COVID-19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies.
Albert Gil-VilaNaveen RAlbert Selva O'CallaghanParikshit SenAlbert Selva-O'CallaghanPrithvi Sanjeevkumar GaurRaquel Arànega GonzalezJames B LillekerMasataka KuwanaVishwesh AgarwalSinan KardeşMinchul KimJessica A DayAshima MakolMarcin MilchertTamer A GheitaBabur SalimTsvetelina V VelikovaAbraham Edgar Gracia-RamosIoannis ParodisElena NikiphorouAi Lyn TanTulika ChatterjeeLorenzo CavagnaMiguel Ángel Saavedra-SalinasSamuel Katsuyuki ShinjoNelly ZiadéJohannes KnitzaMasataka KuwanaOliver DistlerGabriela Arredondo Hector ChinoyVikas AgarwalRohit AggarwalLatika Guptanull nullPublished in: Muscle & nerve (2022)
Seven-day postvaccination ADEs were comparable in patients with IIMs, SAIDs, and HCs, except for a higher risk of rash in IIMs. Patients with dermatomyositis with active disease may be at higher risk, and IBM patients may be at lower risk of specific ADEs. Overall, the benefit of preventing severe COVID-19 through vaccination likely outweighs the risk of vaccine-related ADEs. Our results may inform future guidelines regarding COVID-19 vaccination in patients with SAIDs, specifically in those with IIMs. Studies to evaluate long-term outcomes and disease flares are needed to shed more light on developing future COVID-19 vaccination guidelines.